Pipeline
Endeavor
to Develop Leading Medicines
© 2023 – Endeavor Biomedicines | Privacy Notice | Terms of Use
Pipeline
We are focused on developing transformative medicines by targeting the underlying genetic and cellular causes of disease with best-in-class agents. At Endeavor, we will continue to build and advance our pipeline as we acquire additional assets that show promise in improving patient lives.
Program
Preclinical
Phase 1
Phase 2
Phase 3
ENV-101
Oncology
Hedgehog Inhibitor
Phase 2
ENV-101
IPF
Hedgehog Inhibitor
Phase 2
ENV-101
ENV-101 is a small molecule Hedgehog signaling inhibitor that has demonstrated significant clinical efficacy and safety. We are developing ENV-101 as a precision therapy in multiple types of cancer, as well as in idiopathic pulmonary fibrosis (IPF) – where the Hedgehog pathway is implicated as a driver of the disease.
The clinical effects of ENV-101 have been evaluated in nearly 200 people. Six completed studies have characterized the pharmaceutical properties, including PK/PD in patients with advanced solid tumors and demonstrated a superior safety profile compared to similar therapeutics in this class. Across studies enrolling advanced cancer patients, responses were observed at all doses and in multiple tumor types.
ENV-ONC-101
We are developing ENV-101 for patients with tumor mutations in the Hedgehog pathway, which affect approximately 2% of all cancers. Mutations in this pathway can aberrantly activate downstream signaling resulting in proliferation, survival and metastasis of cancer cells. ENV-101 potently and safely inhibits the activity of the Hedgehog pathway which may have a significant benefit on the lives of cancer patients with these mutations.
Enrollment for this trial is currently closed.
For more information on our trial (NCT05199584): A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations.
ENV-IPF-101
We are developing ENV-101 for patients with idiopathic pulmonary fibrosis (IPF), that has the potential to revolutionize the current standard of care. IPF is characterized by progressive lung scarring and reduction in lung volume. Pathologically, it is a wound that won’t heal.
Enrollment for this trial is currently closed.
For more information on our trial (NCT04968574): A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF).
For more information about our clinical trials please contact us at:
Clinical Trials
IPF
Oncology
Expanded Access
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Egestas sed tempus urna et pharetra pharetra massa massa. Volutpat diam ut venenatis tellus in metus. Ullamcorper malesuada proin libero nunc consequat interdum varius. Fames ac turpis egestas maecenas pharetra convallis posuere. Hendrerit gravida rutrum quisque non. Pellentesque pulvinar pellentesque habitant morbi tristique senectus. Risus pretium quam vulputate dignissim suspendisse.
Quis risus sed vulputate odio ut. Quis eleifend quam adipiscing vitae proin sagittis. Volutpat diam ut venenatis tellus. Arcu dui vivamus arcu felis bibendum ut tristique et egestas. Massa vitae tortor condimentum lacinia quis vel eros donec ac. Tincidunt ornare massa eget egestas purus viverra. Congue eu consequat ac felis donec et odio. Gravida in fermentum et sollicitudin ac. Natoque penatibus et magnis dis parturient montes. Porttitor lacus luctus accumsan tortor posuere ac ut.